Muscarinic acetylcholine receptor blocker
Cas No. | 155-41-9 |
别名 | 甲溴东莨菪碱 |
化学名 | (1R,2R,4S,5S,7s)-7-((3-hydroxy-2-phenylpropanoyl)oxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide |
Canonical SMILES | O=C(C(C1=C([H])C([H])=C([H])C([H])=C1[H])([H])C([H])([H])O[H])O[C@@]2([H])C([H])([H])[C@]3([H])[N+](C([H])([H])[H])(C([H])([H])[H])[C@@](C2([H])[H])([H])[C@@]4([H])O[C@@]34[H].[Br-] |
分子式 | C18H24BrNO4 |
分子量 | 398.29 |
溶解度 | ≥ 19.9mg/mL in DMSO |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Methscopolamine (Pamine) is a muscarinic acetylcholine receptor blocker. Target: mAChRMethylscopolamine is an oral medication used along with other medications to treat peptic ulcers by reducing stomach acid secretion. With the advent of proton pump inhibitors and antihistamine medications it is rarely used for this. It can also be used for stomach or intestinal spasms, to reduce salivation, and to treat motion sickness. From Wikipedia.Methscopolamine (Pamine), an anti-acetylcholine drug, prevented ulcer formation, reduced further volume and acid output but produced a 3-4 fold increase in hexosamine concentration. Tissue (corpus and antrum) hexosamine was moderately reduced by restraint. In the corpus, this was counteracted by methscopolamine but antrum hexosamine was not influenced by this drug. The anti-ulcer property of methscopolamine may be due not only to its effect on acid secretion but also to the rise in gastric mucus concentration that it produced [1]. References: [1]. Robert, A. and J.E. Nezamis, Effect of an Anti-Acetylcholine Drug, Methscopolamine Bromide, on Ulcer Formation and Gastric Mucus. J Pharm Pharmacol, 1964. 16: p. 690-5. [2]. Kong Q, et al. Effects of pharmacological treatments on hippocampal NCAM1 and ERK2 expression in epileptic rats with cognitive dysfunction. Oncol Lett. 2016 Sep;12(3):1783-1791. |